Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses (2019 - 2025)

Historic Operating Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $265.9 million.

  • BridgeBio Pharma's Operating Expenses rose 3672.17% to $265.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $963.7 million, marking a year-over-year increase of 2644.3%. This contributed to the annual value of $814.9 million for FY2024, which is 3214.05% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Operating Expenses of $265.9 million as of Q3 2025, which was up 3672.17% from $244.8 million recorded in Q2 2025.
  • BridgeBio Pharma's Operating Expenses' 5-year high stood at $265.9 million during Q3 2025, with a 5-year trough of $128.0 million in Q1 2023.
  • Over the past 5 years, BridgeBio Pharma's median Operating Expenses value was $175.4 million (recorded in 2022), while the average stood at $178.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 2701.86% in 2023, then soared by 6468.37% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Operating Expenses (Quarter) stood at $178.5 million in 2021, then dropped by 26.55% to $131.1 million in 2022, then skyrocketed by 36.66% to $179.2 million in 2023, then grew by 29.44% to $231.9 million in 2024, then rose by 14.66% to $265.9 million in 2025.
  • Its Operating Expenses was $265.9 million in Q3 2025, compared to $244.8 million in Q2 2025 and $221.0 million in Q1 2025.